Anticoagulant medication adherence for cancer‐associated thrombosis: A comparison of LMWH to DOACs. (21st November 2020)

• Record Type: Journal Article
• Authors: Schaefer, Jordan K.; Li, Mengbing; Wu, Zhenke; Basu, Tanima; Dorsch, Michael P.; Barnes, Geoffrey D.; Carrier, Marc; Griggs, Jennifer J.; Sood, Suman L.
• Is Part Of: Journal of thrombosis and haemostasis. Volume 19:Number 1(2021)
• Page Start: 212
• Page End: 220
• Publication Date: 2020-11-21
• Subjects: direct‐acting oral anticoagulants -- duration of therapy -- low molecular weight heparin -- patient compliance -- venous thromboembolism; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.15153
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract : Essentials It is not clear if patients are less adherent to low molecular weight heparin (LMWH) compared to direct oral anticoagulants (DOACs) for cancer‐associated thrombosis (CAT). We evaluated medication adherence among two propensity‐matched groups of patients with CAT by comparing the proportion of days covered (PDC). Median treatment persistence on DOACs was more than 80 days longer than LMWH. Medication adherence was high (~95%) and was similar with LMWH compared to DOACs. Abstract: Background: Low molecular weight heparin (LMWH) and direct oral anticoagulants (DOACs) are used to treat cancer‐associated thrombosis (CAT). It is not clear if patients are less adherent to LMWH compared to DOACs. Objectives: To compare medication persistence and adherence between LMWH and DOACs. Patients/Methods: We analyzed Optum's de‐identified Clinformatics® Data Mart Database of privately insured adults with cancer diagnosed between January 2009 and October 2015 who were undergoing chemotherapy, immunotherapy, targeted or hormonal therapies; developed CAT; and were treated with an outpatient anticoagulant. The proportion of days covered (PDC) was calculated from the date of anticoagulant prescription until the anticoagulant was switched, stopped, or the study end. Medication adherence was defined as PDC ≥ 80%, ≥95%, and by comparing the mean PDC. Results: Two propensity‐matched groups of 1128 patients were identified. Patient persistence was higher with DOACs compared to LMWH (median 116 days versus 34 days). With adherence defined as PDC ≥ 80%, we found no significant difference (95.6% versus 94.6% adherence with DOACs versus LMWH, P = .33). The mean difference of PDC between the two groups was also similar. With medication adherence defined as PDC ≥ 95%, adherence was evident in 73% of DOAC users and 81% of patients on LMWH ( P < .001). Prescription copayments were higher on average for LMWH compared to DOACs (mean $153.61 versus 40.67; standard deviation $306.74 versus $33.11). Conclusion: Patients remain on DOACs longer than LMWH, but medication adherence is similar with LMWH.